For most people, the intense ache that follows the death of a loved one eventually softens, and daily life resumes. But for ...

A Phase IIa clinical trial finds that a single, brief dose of DMT (from ayahuasca) provides rapid and lasting relief for depression.

The presentation by Dr. Dirk Beher, Chief Executive Officer of FundaMental Pharma, will highlight the scientific foundation for lead candidate FMP374, the distinctive approach to modulating NMDAR, and ...

Researchers found that a single 21.5mg dose of DMT reduced depression symptoms compared to placebo in patients with treatment ...

An AI-based machine learning tool identified depression in 71% of people with the condition from under a minute of free speech. The findings may enable more widespread screening for the condition. The ...

On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...

Neuropsychiatric drug development is rife with clinical trial failures, but Alto Neuroscience aims to overcome these hurdles with a precision medicine approach that matches a patient to a drug. A ...

Almost half of people with depression meet criteria for being ‘treatment-resistant’, found a new study published in the British Journal of Psychiatry. Definitions for treatment-resistant depression ...

A team of leading clinical research scientists from the Departments of Psychiatry and Dermatology at the Icahn School of Medicine at Mount Sinai has found that the serum of patients with major ...